Edition:
United Kingdom

Medigene AG (MDG1k.DE)

MDG1k.DE on Xetra

8.20EUR
9:28am BST
Change (% chg)

€-0.12 (-1.38%)
Prev Close
€8.32
Open
€8.37
Day's High
€8.37
Day's Low
€8.15
Volume
17,557
Avg. Vol
89,260
52-wk High
€16.05
52-wk Low
€7.20

Latest Key Developments (Source: Significant Developments)

Medigene Sells Remaining Rights And Inventories Of Veregen To Aresus
Monday, 8 Apr 2019 

April 8 (Reuters) - Medigene AG ::MEDIGENE SELLS REMAINING RIGHTS AND INVENTORIES OF VEREGEN® TO ARESUS PHARMA.ALL EXISTING RELEVANT CONTRACTS WITH DISTRIBUTION PARTNERS AND EXTERNAL SERVICE PROVIDERS WILL BE TRANSFERRED FROM MEDIGENE TO ARESUS.COMPLETES TRANSFORMATION INTO A PURE IMMUNOTHERAPY COMPANY.MEDIGENE WILL RECEIVE UP TO APPROXIMATELY EUR 7.75 MILLION FROM ARESUS FOR REMAINING VEREGEN® RIGHTS AND ALL EXISTING API STOCK.MEDIGENE'S EBITDA WILL BE AFFECTED BY A NON-CASH EFFECTIVE LOSS BETWEEN EUR 4 AND 5 MIO.EXPECTED PAYMENTS ARE RECOGNIZED AS RECEIVABLES AND DISCOUNTED IN ACCORDANCE WITH INTERNATIONAL FINANCIAL REPORTING STANDARDS.MEDIGENE WILL UPDATE ITS FINANCIAL GUIDANCE WITH RESPECT TO REVENUE AND EBITDA WITH ISSUING ITS QUARTERLY STATEMENT.CLOSING OF TRANSACTION INCLUDING TRANSFER OF RIGHTS IS PLANNED FOR MID-APRIL 2019.  Full Article

Medigene And Roivant Affiliate Cytovant Establish Strategic Partnership
Thursday, 4 Apr 2019 

April 4 (Reuters) - Medigene AG ::PTA-ADHOC: MEDIGENE AG: MEDIGENE AND ROIVANT AFFILIATE CYTOVANT ESTABLISH STRATEGIC RESEARCH AND DEVELOPMENT PARTNERSHIP FOR CELLULAR THERAPIES IN ASIA.MEDIGENE WILL RECEIVE AN OVERALL UPFRONT PAYMENT OF USD 10 MILLION AS WELL AS POTENTIAL DEVELOPMENT.MEDIGENE WILL BE ELIGIBLE TO RECEIVE ROYALTY PAYMENTS ON NET SALES OF PRODUCTS IN A LOW DOUBLE-DIGIT PERCENTAGE IN RELEVANT COUNTRIES.CYTOVANT WILL REIMBURSE ALL RESEARCH AND DEVELOPMENT COSTS INCURRED BY MEDIGENE WITHIN COLLABORATION..TO RECEIVE COMMERCIAL MILESTONE PAYMENTS WHICH IN AGGREGATE COULD TOTAL OVER USD 1 BILLION.  Full Article

Medigene FY Total Revenues Amounted To EUR 7.8 Mln In 2018
Tuesday, 5 Mar 2019 

March 5 (Reuters) - Medigene AG ::FY TOTAL REVENUES AMOUNTED TO EUR 7.8 M IN 2018 (2017: EUR 8.9 M).FY EBITDA LOSS OF EUR 16.3 M (2017: EUR 14.6 M).CASH AND CASH EQUIVALENTS (LIQUID ASSETS AND TIME DEPOSITS) AMOUNTED TO EUR 71.4 M AT END OF YEAR (2017: EUR 51.7 M).  Full Article

Medigene Enters Into Exclusive License Agreement With Helmholtz Zentrum Munich
Friday, 4 Jan 2019 

Jan 4 (Reuters) - Medigene AG ::HAS ENTERED INTO AN EXCLUSIVE LICENSE AGREEMENT WITH HELMHOLTZ ZENTRUM MUNICH (HMGU).LICENSE AGREEMENT FOR A CHIMERIC CO-STIMULATORY RECEPTOR WHICH IS A FUSION PROTEIN OF PD-1 AND 4-1BB.  Full Article

Medigene Publishes Topline Interim Data From Ongoing Phase I/II Clinical Trial
Wednesday, 19 Dec 2018 

Dec 19 (Reuters) - Medigene AG ::MEDIGENE PUBLISHES TOPLINE INTERIM DATA FROM ONGOING PHASE I/II CLINICAL TRIAL WITH DC VACCINES IN AML PATIENTS.MEDIGENE SAYS VACCINATIONS WERE WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS (SAES) RELATED TO TREATMENT IN ONGOING TRIAL.  Full Article

Medigene 9-month Net Loss Up 14 Pct To EUR 12.2 Million
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Medigene AG ::9-MONTH TOTAL REVENUE INCREASED BY 11% TO EUR 8.0 MILLION.9-MONTH EBITDA LOSS INCREASED AS ANTICIPATED BY 5% TO EUR 10.7 MILLION.9-MONTH NET LOSS INCREASED BY 14 % TO EUR 12.2 MILLION DUE TO HIGHER RESEARCH AND DEVELOPMENT EXPENSES AND CURRENCY EFFECTS.FURTHER IMPROVEMENT OF FINANCIAL GUIDANCE 2018.CONTINUES TO EXPECT TOTAL REVENUE OF EUR 9.5 - 10.5 MILLION IN 2018.COMPANY NOW EXPECTS TO SPEND EUR 19 - 21 MILLION FOR FULL YEAR 2018 (PREVIOUS GUIDANCE: EUR 21 - 23 MILLION).EXPECTING TO MAKE A LOSS AT EBITDA LEVEL OF EUR 16 - 18 MILLION (PREVIOUS GUIDANCE: EUR 18 - 20 MILLION) IN 2018.FORECASTS A TOTAL CASH USAGE OF EUR 12 - 14 MILLION FOR 2018 (PREVIOUS GUIDANCE: EUR 15 - 17 MILLION).  Full Article

Medigene AG Says Raised 32.3 Mln EUros In Oversubscribed Private Placement
Thursday, 24 May 2018 

May 24 (Reuters) - Medigene AG ::MEDIGENE SUCCESSFULLY RAISES EUR 32.3 MILLION IN OVERSUBSCRIBED PRIVATE PLACEMENT.ISSUED 2,230,000 NEW SHARES FROM AUTHORIZED CAPITAL, REPRESENTING APPROXIMATELY 10% OF CURRENTLY OUTSTANDING SHARES.SHARES WERE ALLOCATED TO INSTITUTIONAL INVESTORS AT A PRICE OF EUR 14.50 PER SHARE.FINANCING WILL INCREASE TOTAL NUMBER OF REGISTERED SHARES TO 24,544,595.  Full Article

Germany's Medigene AG announces capital increase
Thursday, 24 May 2018 

May 24 (Reuters) - Medigene AG ::SAYS MEDIGENE AG - MEDIGENE ANNOUNCES CAPITAL INCREASE TO FUND IMMUNOTHERAPY PROGRAMS.SAYS EXPECTS TO ISSUE UP TO 2.23 MILLION NEW SHARES FROM AUTHORIZED CAPITAL, WHICH REPRESENTS APPROXIMATELY 10% OF CURRENTLY OUTSTANDING SHARE CAPITAL..  Full Article

Medigene Affirms FY Guidance
Wednesday, 9 May 2018 

May 9 (Reuters) - Medigene AG ::Q1 REVENUES UP 6 PERCENT AT 2.77 MILLION EUROS.Q1 EBITDA LOSS WIDENS BY 6 PERCENT TO 3.19 MILLION EUROS.AFFIRMS FY GUIDANCE FOR EBITDA LOSS OF 21 - 23 MILLION EUROS.SAYS HAS SUFFICIENT RESOURCES TO FUND BUSINESS OPERATIONS BEYOND THE PLANNING HORIZON OF 2 YRS.  Full Article

Medigene Sells US-Rights For Veregen, Raises 2017 Guidance
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - MEDIGENE AG ::PTA-ADHOC: MEDIGENE AG: MEDIGENE SELLS US-RIGHTS FOR VEREGEN® AND RAISES FINANCIAL GUIDANCE 2017.EXPECTS REVENUES OF EUR 10.5-11.5 M INSTEAD OF EUR 8-10 M AS PREVIOUSLY GUIDED.EXPECTS 2017 EBITDA-LOSS OF EUR 14-15 M INSTEAD OF EUR 16-18 M.EXPECTS 2017 CASH UTILIZATION OF EUR 20-22 M INSTEAD OF EUR 23-27 M.  Full Article

German stocks - Factors to watch on March 6

BERLIN/FRANKFURT, March 6 The following are some of the factors that may move German stocks on Wednesday: